Table 1. Characteristics of the study patients (n=1218).
| AdCa | SCCa | |||
|---|---|---|---|---|
| Characteristics | Total | (n=222) | (n=996) | P-value |
| Age, years | ||||
| Mean (range) | 48.2 (24–86) | 46.4 (25–73) | 48.7 (24–86) | 0.006 |
| <30 | 21 (1.7%) | 5 (2.3%) | 16 (1.6%) | 0.177 |
| 30–49 | 715 (58.7%) | 141 (63.5%) | 574 (57.6%) | |
| >50 | 482 (39.6%) | 76 (34.2%) | 406 (40.8%) | |
| FIGO stage | ||||
| IA2 | 88 (7.2%) | 8 (3.6%) | 80 (8.0%) | 0.061 |
| IB1–IB2 | 1019 (83.7%) | 195 (87.8%) | 824 (82.7%) | |
| IIA | 111 (9.1%) | 19 (8.6%) | 92 (9.3%) | |
| Histologic subtype | ||||
| Mucinous | 203 (16.7%) | 203 (16.7%) | — | — |
| Endometrioid | 14 (1.1%) | 14 (1.1%) | — | |
| Serou | 2 (0.2%) | 2 (0.2%) | — | |
| Mixed | 3 (0.2%) | 3 (0.2%) | — | |
| Grade of differentiation | ||||
| Well | 332 (27.3%) | 63 (28.4%) | 269 (27.0%) | 0.366 |
| Moderately | 573 (47.0%) | 94 (42.3%) | 479 (48.1%) | |
| Poorly | 294 (24.1%) | 60 (27.0%) | 234 (23.5%) | |
| Undetermined | 19 (1.6%) | 5 (2.3%) | 14 (1.4%) | |
| Tumour size, cm | ||||
| Mean (range) | 2.4 (0.3–9) | 2.3 (0.3–6) | 2.4 (0.4–9) | 0.286 |
| ⩽2 | 571 (46.9%) | 108 (48.6%) | 463 (46.5%) | 0.147 |
| 2–4 | 510 (41.9%) | 94 (42.3%) | 416 (41.8%) | |
| 4–6 | 114 (9.4%) | 20 (9.0%) | 94 (9.4%) | |
| >6 | 23 (1.9%) | 0. (0.0%) | 23 (2.3%) | |
| Depth of stromal invasion | ||||
| ⩽1/2 | 753 (61.8%) | 135 (60.8%) | 618 (62.0%) | 0.731 |
| >1/2 | 465 (38.2%) | 87 (39.2%) | 378 (38.0%) | |
| Parametrial involvement | ||||
| No | 1106 (90.8%) | 200 (90.1%) | 906 (91.0%) | 0.684 |
| Yes | 112 (9.2%) | 22 (9.9%) | 90 (9.0%) | |
| Resection margin | ||||
| Negative | 1190 (97.7%) | 218 (98.2%) | 972 (97.6%) | 0.585 |
| Positive | 28 (2.2%) | 4 (1.8%) | 24 (2.4%) | |
| LVSI | ||||
| No | 969 (79.6%) | 189 (85.1%) | 780 (78.3%) | 0.023 |
| Yes | 249 (20.4%) | 33 (14.9%) | 216 (21.7%) | |
| Lymph node metastasis | ||||
| No | 1048 (86.0%) | 188 (84.7%) | 860 (86.3%) | 0.518 |
| Yes | 170 (14.0%) | 34 (15.3%) | 136 (13.7%) | |
| PALN metastasis a | ||||
| No | 1204 (98.9%) | 219 (98.6%) | 985 (98.9%) | 0.755 |
| Yes | 14 (1.1%) | 3 (1.4%) | 11 (1.1%) | |
| Adjuvant treatment | ||||
| None | 907 (74.5%) | 159 (71.6%) | 748 (75.1%) | 0.242 |
| Chemotherapy | 86 (7.1%) | 20 (9.0%) | 66 (6.6%) | |
| Radiation therapy | 113 (9.3%) | 26 (11.7%) | 87 (8.7%) | |
| CCRT | 112 (9.2%) | 17 (7.7%) | 95 (9.5%) | |
Abbreviations: AdCa=adenocarcinoma; CCRT=concurrent chemoradiation therapy; FIGO=International Federation of Obstetrics and Gynecology; LVSI=lymphovascular space invasion; PALN=para-aortic lymph node; SCCa=squamous cell carcinoma.
a
A total of 731 patients underwent para-aortic lymphadenectomy.